According to DelveInsight’s evaluation, the global Pulmonary Arterial Hypertension (PAH) pipeline features more than 55 prominent companies actively engaged in developing over 55 therapeutic candidates. The analysis covers clinical trials, treatment approaches, mechanisms of action, routes of administration, and recent advancements.
“Pulmonary Arterial Hypertension Pipeline Insight” by DelveInsight delivers an extensive overview of the current clinical development landscape along with future growth opportunities within the PAH market.
The PAH pipeline study provides a detailed commercial and clinical evaluation of drug candidates, spanning from preclinical research to marketed products. It also includes comprehensive drug profiles describing mechanisms of action, clinical trial progress, regulatory milestones such as NDA approvals (where applicable), and development activities including technology platforms, partnerships, mergers and acquisitions, funding updates, special designations, and other product-specific insights.
Key Highlights from the Pulmonary Arterial Hypertension Pipeline Report
- Pulmonary Arterial Hypertension companies worldwide are consistently working on innovative PAH therapies, achieving notable progress in recent years.
- Pulmonary Arterial Hypertension companies actively involved in PAH treatment development include Aerovate Therapeutics, Novartis, Keros Therapeutics, Vigonvita Life Sciences, Insmed Incorporated, Chugai Pharmaceutical, Merck & Co., Janssen Pharmaceuticals, Actelion, Gossamer Bio, Lung Biotechnology PBC, United Therapeutics, Gilead Sciences, Acceleron Pharma, Eiger BioPharmaceuticals, AstraZeneca, and several others.
- Promising Pulmonary Arterial Hypertension therapies under clinical evaluation include AV-101, LTP001, KER-012, TPN171H, Treprostinil Palmitil, Satralizumab, Sotatercept, Macitentan, ACT-293987, GB002 (seralutinib), Parenteral Treprostinil, Ralinepag, Selonsertib, Ubenimex, Olaparib, and others, all expected to influence the Pulmonary Arterial Hypertension market significantly in the coming years.
Recent Developments in the Pulmonary Arterial Hypertension Pipeline
- December 2025: tiakis Biotech AG announced completion of a comprehensive preclinical data package to support Phase II development of Tiprelestat for PAH. Tiprelestat is a first-in-class neutrophil elastase inhibitor and BMPR2 enhancer designed as a disease-modifying therapy aimed at reducing inflammation and reversing vascular remodeling in PAH.
- November 2025: Inhibikase Therapeutics revealed plans to move IKT-001 into a global pivotal Phase III study, IMPROVE-PAH, expected to begin in early 2026.
- November 2025: Cereno Scientific submitted a clinical trial application to the FDA for its oral candidate CS1, a repurposed epilepsy drug, to assess its impact on quality of life and survival in PAH patients. Pending approval, the Phase IIb study is projected to launch in the first half of 2026.
- September 2025: AllRock Bio secured $50 million in Series A funding to advance ROC-101, an oral pan-ROCK inhibitor licensed from Sanofi, into Phase II trials targeting PAH and ILD-associated pulmonary hypertension.
- August 2025: Cereno Scientific’s CS1 received FDA Fast Track designation for PAH treatment.
- August 2025: VASTHERA Co., Ltd. obtained FDA IND clearance for VTB-10, a novel enzyme-based therapy developed using its Redoxizyme™ platform, to enter Phase I testing.
- March 2025: Merck announced positive Phase III ZENITH trial results for WINREVAIR™ (sotatercept), showing a 76% reduction in major morbidity and mortality risk compared to placebo in high-risk PAH patients.
- January 2025: Additional preliminary ZENITH trial data from Merck reinforced the strong efficacy profile of WINREVAIR in advanced PAH.
- October 2024: Inhibikase Therapeutics completed a $110 million private placement to fund its Phase IIb PAH study and broader pipeline efforts.
Get a Free Sample PDF Report to know more about Pulmonary Arterial Hypertension Pipeline Therapeutic Assessment – Pulmonary Arterial Hypertension Clinical Trials and FDA Approvals
Pulmonary Arterial Hypertension Overview
Pulmonary Arterial Hypertension is a rare and progressive disorder marked by elevated blood pressure in the pulmonary arteries. This increased pressure strains the right side of the heart, leading to symptoms such as breathlessness, fatigue, chest discomfort, and fluid retention in the legs. PAH may occur without a known cause, be inherited, or develop alongside other conditions like connective tissue disorders or congenital heart disease. Although no cure exists, treatments including targeted medications, oxygen therapy, and lifestyle adjustments help manage symptoms and enhance patient quality of life.
Emerging Pulmonary Arterial Hypertension Drugs Under Different Phases of Clinical Development Include:
- TYVASO/TYVASO DPI/TREPROST Inhalation Solution (treprostinil): United Therapeutics/Mochida Pharmaceutical
- OPSYNVI/YUVANCI (macitentan and tadalafil): Johnson & Johnson
- WINREVAIR (sotatercept): Merck
- UPTRAVI (selexipag): Johnson & Johnson/ Nippon Shinyaku
- AV-101: Aerovate Therapeutics
- LTP001: Novartis
- KER-012: Keros Therapeutics
- TPN171H: Vigonvita Life Sciences
- Treprostinil Palmitil: Insmed Incorporated
- Satralizumab (Genetical Recombination): Chugai Pharmaceutical
- Sotatercept: Merck Sharp & Dohme
- Macitentan: Janssen Pharmaceutical
- ACT-293987: Actelion
- GB002 (seralutinib): Gossamer Bio
- Parenteral Treprostinil: Lung Biotechnology PBC
- Ralinepag: United Therapeutics
- Selonsertib: Gilead Sciences
- Sotatercept: Acceleron Pharma
- ubenimex: Eiger BioPharmaceuticals
- Olaparib: AstraZeneca
Further Pulmonary Arterial Hypertension product details are provided in the report. Download the Pulmonary Arterial Hypertension pipeline report to learn more about the emerging Pulmonary Arterial Hypertension therapies
Pulmonary Arterial Hypertension Route of Administration Categories
Pipeline therapies are classified by delivery method, including oral, parenteral, intravitreal, subretinal, and topical formulations.
Pulmonary Arterial Hypertension Molecule Type Classification
PAH drug candidates fall under various molecular classes such as monoclonal antibodies, peptides, polymers, small molecules, and gene therapies.
Pulmonary Arterial Hypertension Therapeutic Assessment Framework
The report evaluates Pulmonary Arterial Hypertension therapies by:
- Product type
- Development stage
- Route of administration
- Molecular class
DelveInsight’s PAH pipeline database includes more than 55 investigational products spanning Phase III, Phase II, Phase I, preclinical, discovery, and discontinued stages.
The report provides expanded insights into each candidate therapy and can be accessed to explore detailed drug development information.
Download Sample PDF Report to know more about Pulmonary Arterial Hypertension drugs and therapies
Leading Pulmonary Arterial Hypertension Companies in the Therapeutics Space
Key organizations contributing to PAH drug development include VasThera, Altavant Sciences, Alterras Therapeutics, United Therapeutics, Chiesi Farmaceutici, Gmax Biopharm, Antlia Bioscience, and others.
Pulmonary Arterial Hypertension Pipeline Analysis:
The Pulmonary Arterial Hypertension pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Pulmonary Arterial Hypertension with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pulmonary Arterial Hypertension Treatment.
- Pulmonary Arterial Hypertension key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Pulmonary Arterial Hypertension Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pulmonary Arterial Hypertension market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Pulmonary Arterial Hypertension drugs and therapies
Pulmonary Arterial Hypertension Pipeline Market Drivers
- Rising prevalence of Pulmonary Arterial Hypertension worldwide, robust Drug pipeline and the new product combinations are some of the important factors that are fueling the Pulmonary Arterial Hypertension Market.
Pulmonary Arterial Hypertension Pipeline Market Barriers
- However, high cost associated with the treatment of Pulmonary Arterial Hypertension, lack of awareness among people in developing countries and other factors are creating obstacles in the Pulmonary Arterial Hypertension Market growth.
Scope of Pulmonary Arterial Hypertension Pipeline Drug Insight
- Coverage: Global
- Key Pulmonary Arterial Hypertension Companies: Aerovate Therapeutics, Novartis, Keros Therapeutics, Vigonvita Life Sciences, Insmed Incorporated, Chugai Pharmaceutical, Merck Sharp & Dohme, Janssen Pharmaceutical, Actelion, Gossamer Bio, Lung Biotechnology PBC, United Therapeutics, Gilead Science, Acceleron Pharma, Eiger BioPharmaceuticals, AstraZeneca, and others
- Key Pulmonary Arterial Hypertension Therapies: AV-101, LTP001, KER-012, TPN171H, Treprostinil Palmitil, Satralizumab (Genetical Recombination), Sotatercept, Macitentan, ACT-293987, GB002 (seralutinib), Parenteral Treprostinil, Ralinepag, Selonsertib, Sotatercept, ubenimex, Olaparib, and others
- Pulmonary Arterial Hypertension Therapeutic Assessment: Pulmonary Arterial Hypertension current marketed and Pulmonary Arterial Hypertension emerging therapies
- Pulmonary Arterial Hypertension Market Dynamics: Pulmonary Arterial Hypertension market drivers and Pulmonary Arterial Hypertension market barriers
Request for Sample PDF Report for Pulmonary Arterial Hypertension Pipeline Assessment and clinical trials
Table of Contents
1. Pulmonary Arterial Hypertension Report Introduction
2. Pulmonary Arterial Hypertension Executive Summary
3. Pulmonary Arterial Hypertension Overview
4. Pulmonary Arterial Hypertension- Analytical Perspective In-depth Commercial Assessment
5. Pulmonary Arterial Hypertension Pipeline Therapeutics
6. Pulmonary Arterial Hypertension Late Stage Products (Phase II/III)
7. Pulmonary Arterial Hypertension Mid Stage Products (Phase II)
8. Pulmonary Arterial Hypertension Early Stage Products (Phase I)
9. Pulmonary Arterial Hypertension Preclinical Stage Products
10. Pulmonary Arterial Hypertension Therapeutics Assessment
11. Pulmonary Arterial Hypertension Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Pulmonary Arterial Hypertension Key Companies
14. Pulmonary Arterial Hypertension Key Products
15. Pulmonary Arterial Hypertension Unmet Needs
16 . Pulmonary Arterial Hypertension Market Drivers and Barriers
17. Pulmonary Arterial Hypertension Future Perspectives and Conclusion
18. Pulmonary Arterial Hypertension Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a specialized life sciences market research and consulting firm providing end-to-end strategic solutions for pharmaceutical companies. Its healthcare consulting services support market intelligence, growth planning, and business strategy development through data-driven and practical approaches.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/epidemiology-analysis